THERAPY DOSSIER · th-3122419b74fb

Microglial exosomal miR-124-3p

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28935818 ↗2017Reported benefit

Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons.

MouseTBIUnspecifiedC57BL/6Male

Model: Repetitive traumatic brain injury in mice, with in vitro scratch-injured neurons and BV2 microglia

miR-124-3p was the most increased miRNA in microglial exosomes after injury. It promoted M2 microglial polarisation, inhibited neuronal inflammation, promoted neurite outgrowth with reduced RhoA, amyloid-beta and phosphorylated tau, and improved neurological outcome and reduced neuroinflammation in…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…